Other Publication Details
Mandatory Fields
Reviews
Newland, B;Dunnett, SB;Dowd, E
2016
August
Targeting delivery in Parkinson's disease
Published
1
Optional Fields
LACTOFERRIN-MODIFIED NANOPARTICLES FACTOR GENE-THERAPY GLIAL-CELL LINE STEM-CELLS NEUROTROPHIC FACTOR DOPAMINE NEURONS RAT MODEL HEMIPARKINSONIAN RATS SUBSTANTIA-NIGRA DRUG-DELIVERY
Disease-modifying therapies for Parkinson's disease (PD), with the potential to halt the neurodegenerative process and to stimulate the protection, repair, and regeneration of dopaminergic neurons, remain a vital but unmet clinical need. Targeting the delivery of current and new therapeutics directly to the diseased brain region (in particular the nigrostriatal pathway) could result in greater improvements in the motor functions that characterise PD. Here, we highlight some of the opportunities and challenges facing the development of the next generation of therapies for patients with PD.
OXFORD
ELSEVIER SCI LTD
1359-6446
1313
1320
10.1016/j.drudis.2016.06.003
Grant Details
Publication Themes